Item 8.01 Other Events.
As previously reported, on February 21, 2020, BioSig Technologies, Inc. (the
"Company") entered into an underwriting agreement (the "Underwriting Agreement")
with Laidlaw & Company (UK) Ltd. (the "Underwriter") relating to an underwritten
public offering of 2,500,000 shares (the "Shares") of the Company's common
stock, $0.001 par value per share (the "Common Stock"). On February 25, 2020,
the offering of the Shares closed, and pursuant to the Underwriting Agreement,
the Company issued to the Underwriter and its designees warrants to purchase up
to an aggregate 125,000 shares of Common Stock at a price per share equal to
$4.80. On February 25, 2020, the Company issued a press release announcing the
closing of such offering. A copy of the press release is attached as Exhibit
99.1 to this Current Report on Form 8-K and is hereby incorporated by reference
herein.
On February 26, 2020, the Company issued a press release announcing that the
Company will be presenting at the Cowen & Co. 40th Annual Health Care
Conference. A copy of the press release is attached as Exhibit 99.2 to this
Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
99.1 Press Release, dated February 25, 2020
99.2 Press Release, dated February 26, 2020
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses